Pfizer Naloxone Access Program

For more than 30 years, Pfizer has developed and implemented a variety of innovative public-private partnerships designed to address unmet medical needs and global public health issues. Today we operate several patient assistance programs that expand access to potentially lifesaving medicines and provide educational resources for patients and physicians.

The Pfizer Naloxone Access Program reflects Pfizer’s longstanding commitment to improve health outcomes by expanding access to medicines and ensuring patient safety through educational activities associated with appropriate use of prescription medicines.

THE NEED*

Opioid overdose is a growing public health epidemic in the United States. Misuse, abuse, and addiction are serious potential dangers relating to prescription opioids. According to the U.S. Center for Disease Control and Prevention:

- 78 PEOPLE EVERY DAY
  Die from prescription opioid-related overdose

- AGES 25-54
  Are most at risk

- MOST INCIDENTS
  Occur outside of a medical setting, such as in a home

- 2 MILLION
  Americans abused or were dependent on prescription opioids in 2014

ECONOMIC IMPACT

- $55 billion in health and social costs per year
- $20 billion in emergency department and inpatient care

In March 2015, HHS Secretary Sylvia M. Burwell announced an initiative targeting 3 priority areas:

1. Improving prescribing practices
2. Expanding access to and use of medication-assisted treatment
3. Expanding the use of naloxone

The Pfizer Naloxone Access Program is comprised of 2 key elements:

1. Pfizer Donation of up to 1 Million Naloxone Hydrochloride Injection, USP Doses to Direct Relief Over Four Years (250,000 per Year)

   - Who is eligible for the donation?
     - Direct Relief’s nationwide network of more than 4,000 nonprofit sites, including charitable clinics, federally qualified health centers, community clinics, and public health departments in all 50 states and the District of Columbia

   - What is the cost?
     - Pfizer Inc is providing the product at no cost for Direct Relief to distribute to members in their network

   - How much is available?
     - Up to 250,000 doses per year

   - When will it be available?
     - Donated Naloxone Hydrochloride Injection, USP is available beginning in mid to late Q1 2017

   **Direct Relief**
   - Administers Pfizer’s Diflucan Partnership Program, various OTC, Rx and vaccine donations for emergency and disaster relief
   - Only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all 50 states and the District of Columbia

2. $1 Million Opioid Overdose Grant Across Five U.S. States

   - Pfizer Inc to provide a $1 million charitable grant to fund initiatives focused on increasing public awareness of risks of opioid addiction
   - 5 states (Illinois, Massachusetts, New Mexico, New York, and Tennessee) to receive individual grants of $200,000 using a defined selection criteria

   **State Selection Criteria**
   - States with highest incidence of opioid dependence and death as reported by CDC
   - States with largest drug abuse admissions
   - States that have implemented Naloxone/Good Samaritan laws


   **Additional Program Information:**
   - The Pfizer Naloxone Access Program will also sustain Hospira’s longtime assistance to a network of opioid abuse prevention and treatment centers, community groups and patient advocates. Pfizer will double this commitment over the next year to include 40 organizations which focus on supporting and reducing harm to individuals impacted by substance abuse. In addition, we will expand access to naloxone to Emergency Medical Services.

   *In September 2015, Pfizer officially acquired Hospira, a leading provider of sterile injectable medicines*